Many therapeutic strategies for end-stage renal disease (ESRD) patients have failed to exhibit survival improvement in large-scale randomized controlled trials (RCTs). The current review gives an overview on the medical strategies for treatment of ESRD patients that have previously been tested in RCTs with mortality reduction as pre-specified study endpoint. We identified 19 RCTs with the following therapeutic strategies: haematocrit increase by erythropoietin (n = 1), growth hormone application (n = 1), lipid-lowering by statins (n = 3), renin-angiotensin system blockage (n = 4), β-receptor blockage (n = 1), homocysteine lowering (n = 5), application of anti-oxidative substances (n = 2), omega-3-fatty-acid supplementation (n = 1) and calcium-free phosphate binders (n = 1). While several of these studies were able to demonstrate reductions in hard cardiovascular endpoints such as myocardial infarction, survival improvement in ESRD patients was demonstrated in only three studies. The substances tested in these three trials were telmisartan, candesartan and carvedilol. In summary, most pharmaceutical monointerventions failed to reduce mortality in ESRD patients, i.e. a multi-morbid population. Apart from the issues relating to future trial design, this raises the question of whether we need multi-faceted interventions to improve this dismal situation. Until then, nephrologists are left with little evidence and lots of opinions.
Introduction
Recent US registry data [1] documented an annual mortality rate exceeding 20% in chronic haemodialysis patients. Cardiovascular events are the main driving force for this excess mortality [2] . End-stage renal disease (ESRD) mortality is characterized by the pathogenetic complexity of the underlying cardiovascular disease which exhibits a very heterogeneous risk factor profile. Based on the diverse pathophysiology and the multifaceted clinical picture of cardiovascular disease in ESRD, it appears challenging to imagine that a single interventional tool could show convincing therapeutic success in terms of survival improvement. Indeed, the history of mortality-driven large prospective randomized controlled intervention trials (RCTs) in nephrology has long been characterized by disappointingly 'negative' results. Consequently, there is a remarkable lack of evidence regarding medical treatment strategies to reduce cardiovascular and/or all-cause mortality in ESRD patients.
Thus, in general, the restoration of cardiovascular health in ESRD by mono-therapeutic approaches may be challenging, if not impossible. It is conceivable that only a multitarget intervention may overcome this hurdle.
The intention of the present review is to give a comprehensive overview of previously published trials examining possible medical therapeutic options to improve survival in dialysis patients. This review analyses solely prospective randomized intervention studies. We did not analyse primary patient data, since, rather than presenting a meta-analysis on one particular intervention (intervention strategy), our intention was to support the reader with an overview of the substances which have so far undergone prospective controlled testing in terms of mortality in ESRD. Moreover, we systematically applied the Jadad scale [3] to the identified trials in order to allow the reader a judgement on study quality. This scale assesses the trial quality by analysing random assignment, double blinding and description of patient flow (e.g. drop-outs) with five points representing the highest study quality. Study quality was assessed by two authors (R.K., V. M.B.) (see Supplementary data, Table S1 ). and placebo. The search strategy was limited to human RCTs in any language. To identify other relevant studies, we manually scanned the reference list of review articles and all included trials.
We included prospective RCTs in patients with ESRD which compared medical treatment options (oral, intravenous or subcutaneous route) in primary or secondary prevention of all-cause and/or cardiovascular mortality as either singular or composite endpoint. Studies with retrospective design, post hoc analyses after treatment group allocation, cohort studies or observational studies were excluded. We did not analyse studies investigating mortality effects of dialysis mode, dialysis dose and dialysis timing [4, 5] .
R.K. and V.M.B. independently screened titles and abstracts of potentially relevant articles. Articles which were considered to be relevant by both authors were reviewed as full text. A total of 440 potentially relevant citations were detected and screened; of which, 24 articles were selected for full-text analysis (Figure 1) . Overall, 19 studies fulfilled eligibility criteria (Table 1) . We included three studies with mixed patient cohorts (both non-dialysis CKD and a significant proportion of ESRD patients) [6] [7] [8] . One prospective randomized study was additionally included which reported mortality data, although the definition of endpoints was not explicitly mentioned [9] .
Studies tackling mortality in ESRD: general descriptions Table 1 presents an overview of the 19 studies included. Three studies included a mixed patient cohort with CKD as well as ESRD patients {number of ESRD patients n = 751 (37%) in HOST [6] , n = 3023 (33%) in SHARP [7] and n = 267 (85%) in ASFAST [8] }. Four studies included patients on peritoneal dialysis {number not mentioned in HOST, n = 496 (5.4%) in SHARP, n = 75 (24%) in ASFAST [8] and n = 42 (8%) in Wrone et al. [10] }. The study design was double-blind in 13 out of 19 trials, while 6 trials used an open-label design (Table 2) . Regarding control groups, the majority of the trials listed used a placebo arm (13 out of 19). AHD, anti-hypertensive drugs; ARB, angiotensin receptor blocker; AP, angina pectoris; BP, blood pressure; CAD, coronary artery disease; CVD, cardiovascular disease; CHF, congestive heart failure; GFR, glomerular filtration rate; HD, haemodialysis; LDL-C, LDL cholesterol; LVH, left ventricular hypertrophy; LVEF, left ventricular ejection fraction; MI, myocardial infarction; n.r., not reported; NYHA, New York Heart Association; PVD, peripheral vascular disease; PD, peritoneal dialysis; TIA, transient ischaemic attack. a Jadad scores, ranging from 0 to 5, where 5 indicates highest study quality in terms of randomization, blinding and documentation of patient flow (see Supplementary data, Table S1 ). b Randomization after 1 year.
Two studies [9, 11] , included a non-treatment group as control, whereas the DCOR [12] trial compared two different kinds of phosphate binders. Three studies randomized patients between a low-dose versus a highdose study arm [10, 13, 14] . The definition of the primary endpoint was highly variable between studies (Table 3) . A P-value below 0.05 was generally considered as statistically significant. The Jadad scale (Oxford quality scoring system) [3] was distributed as follows (Supplementary data, Table S1 ): 4-5 points (good quality): 12 studies, fair quality (2-3 points): 7 studies. No studies with poor quality (0-1 points) were included.
Particular medical interventions and effects on mortality in ESRD
Increasing haemoglobin levels by erythropoietin Partial anaemia correction was shown to reduce left ventricular hypertrophy (LVH) [15] , which is one of the driving forces for cardiovascular mortality in ESRD patients [16] . Besarab et al. randomized 1233 long-term haemodialysis patients to receive flexible dosages of epoetin alpha to achieve and maintain haematocrit values of either 42 ± 3 or 30 ± 3%. The study was stopped prematurely due to safety concerns. None of the other cardiovascular secondary endpoints (e.g. non-fatal myocardial infarction) reached statistical significance. In contrast, the authors showed that 'mortality rate in the normal haematocrit group was higher than in the low-haematocrit group for any given range of haematocrit values' [14] . The lack of effectiveness in terms of mortality reduction by increasing haemoglobin (or haematocrit) levels closer to normal was confirmed in several subsequent RCTs in CKD (non-ESRD) patient cohorts [16] [17] [18] . Therefore, current treatment guidelines define haemoglobin levels between 11 and 12 g/L as the target range for erythropoietin use in ESRD patients [19] . The KDOQI guidelines recommend that in ESRD patients with erythropoiesisstimulating agent treatment, Hb levels should not exceed 13 g/L [20] .
In summary, there is substantiated evidence available that overcorrection of Hb levels towards normal in ESRD patients may cause more harm than benefit. 
Growth hormone treatment
The Opportunity trial investigated the effects of daily growth hormone application in haemodialysis patients [21] . The authors selected haemodialysis patients with hypoalbuminaemia below 4.0 g/dL. Since the patient recruitment was slower than anticipated, the sponsor stopped the trial prematurely after a mean trial duration of 20 weeks.
The trial failed to demonstrate statistically significant differences for all-cause mortality, cardiovascular mortality or time to first cardiovascular event. This may in part be explained by the premature termination that led to smaller numbers of patients being followed for shorter periods of time. However, growth hormone effects on soft endpoints such as serum albumin or exercise capacity also failed to show the anticipated significant differences.
Cholesterol-lowering treatment
In non-renal patients, statin therapy reduces the incidence of cardiovascular events and mortality in patients at high cardiovascular risk [22, 23] . Three prospective intervention trials dealing with statin therapy in ESRD patients are available. The first two studies (4D [2] and AURORA [24] ) yielded similar negative outcomes regarding the combined primary endpoint and mortality-i.e. no benefit in dialysis patients despite significant reductions in lowdensity lipoprotein (LDL) cholesterol levels (∼40% in both studies). On the one hand, 4D observed a significant reduction in all cardiac events combined in the atorvastatin arm [RR 0.82, 95% confidence interval (CI) 0.68-0.99, P = 0.03]. However, more cases of fatal stroke occurred in the atorvastatin group (RR 2.03, 95% CI 1.05-3.93, P = 0.04). Remarkably, the incidence of acute myocardial infarction-a major cardiovascular event representing a typical statin target-occurred in only 9% of the total 4D cohort. In the Assessment of Survival and Cardiovascular Events (AURORA) trial, rosuvastatin treatment had no significant effect on the combined primary endpoint, i.e. death from cardiovascular causes, non-fatal myocardial infarction or non-fatal stroke or all-cause mortality [24] ( Table 3) . The SHARP trial [7] included ∼6000 CKD and 3000 ESRD patients with a mean follow-up of 5 years. Patients were assigned to receive either 20 mg simvastatin plus 10 mg ezetimibe or placebo. In contrast to AURORA and 4D, the SHARP study was designed as a trial for primary prevention since a history of coronary artery disease (CAD) was an exclusion criterion. Moreover, while 4D and AURORA tested arteriosclerotic events as endpoints, SHARP defined a combined atherosclerotic endpoint. This combined atherosclerotic endpoint (non-fatal myocardial infarction or coronary death, non-haemorrhagic stroke or arterial revascularization) exhibited a relative risk reduction of 17% compared with placebo in the entire study population.
Overall, the SHARP trial revealed significant reductions in the combined primary endpoint, but also failed to reduce all-cause or cardiovascular mortality. The current ESC guidelines for the management of dyslipidaemias [25] state that CKD is acknowledged as the equivalent to CAD and the guidelines declare LDL cholesterol reductions as the primary target for therapy (class I, level A recommendation). For patients with CKD stages 2-4, there is a class IIa level B recommendation that LDL cholesterol lowering reduces cardiovascular disease risk in CKD patients, and a IIa level C recommendation defines the LDL cholesterol target range below 70 mg/dL. The guidelines do not give recommendations for dialysis patients.
Lowering homocysteine levels
A number of observational studies point towards an association between hyperhomocysteinaemia and cardiovascular morbidity and mortality in non-CKD patients [26] [27] [28] . As CKD patients obtain high rates of cardiovascular mortality and exhibit greatly increased homocysteine concentrations [29] , a homocysteine-lowering therapy was thought to affect the incidence of cardiovascular events and mortality in this population. Indeed, CKD patients in the Homocysteinemia in Kidney and End-Stage Renal Disease (HOST) study achieved a significant reduction in their homocysteine level (−26%) by oral treatment with folic acid, pyridoxine hydrochloride and vitamin B 12 compared with the placebo group [6] . However, this did not translate into better outcome. Heinz et al. [13] also combined vitamin B 12 and folic acid: despite a significant reduction in homocysteine (−35%), there was no significant effect on total mortality or on the risk of cardiovascular events [13] . Of note, two other RCTs (Vianna et al. [30] and ASFAST [8] ) compared folic acid treatment with placebo and one trial [10] compared different dosages of folic acid in ESRD patients. Again, all failed to show a significant effect on their primary endpoint (composite of cardiovascular events, see Table 3 for details) or on cardiovascular mortality.
Anti-oxidants
Oxidative stress is increased in ESRD patients [31, 32] and has been related to increased cardiovascular risk [33] . Consequently, the Secondary Prevention with Antioxidants of Cardiovascular disease in End-stage renal disease (SPACE) study tested whether oral treatment with vitamin E reduces the incidence of cardiovascular events in ESRD patients with pre-existing cardiovascular disease [34] . Despite a significant reduction (−47%) in the primary endpoint (i.e. myocardial infarction, peripheral vascular disease or unstable angina) by vitamin E treatment (Table 3) , there was no significant reduction in cardiovascular or all-cause mortality ( Table 4 ). The authors state that the study was not designed to detect differences in the incidence of fatal cardiovascular events nor was it powered to do so.
A small, monocentric study by Tepel et al. showed that acetylcysteine significantly reduced cardiovascular events (Table 3 ), but again no significant effect on all-cause or cardiovascular mortality was noted (Table 4 ) [35] . The present data from anti-oxidant trials in ESRD need to be reconfirmed since the available data come from rather small study cohorts. Future trials might identify potentially important outcome effects of anti-oxidants when focusing on particular subgroups of ESRD patients, e.g. those in chronic inflammatory state. [54] n.r. n.r. n.r. n.r. n.r. n.r. n.r. n.r. Svensson et al. [42] 30 (29) versus 34 (33) -/1.12 0.69-1.83 0.65 n.r. n.r. n.r. n.r. Takahashi et al. [9] 8 (19) versus 0 (0) n.r. n.r. <0.01 n.r. n.r. n.r. n.r. ASFAST [8] n.r. n.r. n.r. n.r. 24 (13) versus 21 (15) n.r. n.r. n.s. HOST [6] 436 (43) [30] n.r. n.r. n.r. n.r. 15 (16) versus 21 (23) n.r. n.r. 0.47 Suzuki et al. [11] 38 (21) versus 25 (14) 0.64/-0.39-1.06 0.1 n.r. n.r. n.r. n.r. AURORA [24] 660 (48) This study had three treatment arms (i) 1, (ii) 5, and (iii) 15 mg folic acid. n.r., not reported; n.s., non significant.
N-3 polyunsaturated fatty acids
N-3 polyunsaturated fatty acids (PUFA) reduce plasma lipids [36] , lower blood pressure [37] and exhibit antiatherosclerotic [38] , anti-thrombotic [39] , anti-inflammatory [40] as well as anti-arrhythmic properties [41] . Svensson et al. [42] tested in 206 ESRD patients with documented cardiovascular disease whether PUFA treatment has an effect on total cardiovascular events and death. Although they could not report a significant reduction in their primary endpoint (Table 3) or all-cause mortality (Table 4) , they observed a significant reduction in the number of myocardial infarctions in the PUFAtreated group (hazards ratio 0.3, 95% CI 0.1-0.92, P = 0.036). Recent hyperlipoproteinaemia ESC guidelines come to the conclusion that data regarding potential benefits of PUFA in patients at risk are still inconclusive, and the guidelines explicitly caution about the potential risk of bleeding with PUFA therapy [25] . The latter is a clear caveat for the widespread usage of fish oil in ESRD patients in whom bleeding risk is increased, and underlying heart disease often necessitates the parallel usage of anti-platelet agents or oral anti-coagulants.
Sevelamer hydrochloride
The presence and extent of cardiovascular calcification in haemodialysis patients strongly predict an increased mortality [43] [44] [45] . Calcium-containing phosphate binders may contribute to this process [43, 46, 47] . The Dialysis Clinical Outcomes Revisited (DCOR) trial, therefore, asked whether the calcium-free phosphate binder sevelamer hydrochloride reduces mortality rates in haemodialysis patients when assessed in comparison to calcium-containing phosphate binders [12] . There was no significant effect on all-cause or cardiovascular mortality in patients treated with sevelamer (Table 4) . Only a post hoc analysis showed a survival benefit in elderly dialysis patients (older than 65 yrs) and patients with a dialysis dose of more than 2 years. Thus, the debate about the optimal phosphate-binding therapy is still ongoing.
Inhibition of the renin-angiotensin system
To date, four prospective controlled studies have investigated the effects of either angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin-receptor blockers (ARB) on hard endpoints and survival in dialysis patients [9, 11, 12, 48] . Takahashi et al. published the smallest study in the present review with n = 80 patients at baseline. The authors investigated in Japanese haemodialysis patients whether candesartan at a dose of 4-8 mg/day (versus no treatment) reduced the incidence of cardiovascular events (Table 3) . During the follow-up period of 19.4 months, seven patients (16%) in the candesartan group versus 17 patients (46%) in the control group had cardiovascular events. The authors also noted a significant overall reduction in mortality in the study arm with candesartan compared with controls (0 versus 19.8%) ( Table 4) . Some details of the study cohort warrant special attention and limit the ability to extrapolate these findings to the general ESRD population: a history of overt cardiovascular disease was an exclusion criterion.
Moreover, the body mass index was low (mean 20.5 kg/ m²) as was the mean haemoglobin level (∼9 g/dL).
The Fosinopril in Dialysis (FOSIDIAL) study was the first prospective RCT to analyse ACE-I treatment in ESRD patients [49] . No significant benefit for fosinopril treatment was observed in regard to endpoint reduction (Table 3 ) and all-cause mortality (Table 4) . However, there was a baseline imbalance between the two study arms in terms of higher prevalence of cardiovascular disease in the fosinopril arm. Thus, it is possible that the negative outcome of this trial may at least in part be explained by suboptimal randomization.
Suzuki et al. [11] analysed, in 366 Japanese patients, the effect of ARB treatment using different compounds (n = 91 candesartan, n = 59 valsartan and n = 30 losartan) versus no treatment (control group) on cardiovascular events ( primary endpoint) and all-cause mortality (secondary endpoint). The authors reported a significant effect of ARB therapy on the primary endpoint (Table 3) , whereas a significant reduction in all-cause mortality could not be observed (Table 4 ) [11] . This study was conducted in a cohort of patients with a low prevalence of CAD (4%) and congestive heart failure (16%). The usage of β-blockers was low (4%) and the usage of ACE-I was an exclusion criterion.
In contrast, especially high-risk patients were investigated by Cice et al. [48] in 2010. The authors investigated whether telmisartan (maximum dose 80 mg/day) decreases all-cause and cardiovascular mortality and morbidity in haemodialysis patients with chronic heart failure and impaired left ventricular ejection fraction (LVEF) when added to standard therapies with ACE-I [48] . In this very special patient population, the authors observed a significant reduction in all-cause mortality and cardiovascular mortality with telmisartan treatment (Table 4 ) [48] .
Carvedilol
The rationale for using β-blockers in patients with advanced CKD or ESRD is targeting uraemic 'sympathetic overactivity' [50] . Cice et al. [51] tested whether carvedilol therapy could change left ventricular volumes, ejection fraction (LVEF) and symptoms of heart failure (NYHA class) in haemodialysis patients with dilated cardiomyopathy ( primary endpoints). The trial included dialysis patients with an LVEF below 35%. A total of 97% of these patients also received ACE-I. The authors reported a significant improvement in the primary endpoints after 1 year of carvedilol treatment (maximum dosage 25 mg) [51] . As secondary endpoints, they reported a significant reduction in all-cause and cardiovascular mortality after 2 years of treatment (Table 4) [52] . It is important to mention that the effects of β-blockers on mortality reduction in patients primarily presenting with heart failure may not be regarded as class effects. Bucindolol failed to exhibit survival benefits in heart failure patients [53] . Instead, carvedilol, metoprolol and bisoprolol are the β-blockers of choice in patients with congestive heart failure in the general population. We administer routinely carvedilol or metoprolol as our first choice in patients with CKD and ESRD.
What are the conclusions for everyday nephrology patient care?
Convincing data from high-quality RCTs showing reductions in either cardiovascular or all-cause mortality in ESRD patients by application of medications are sparse. Remarkably, data from Tables 3 and 4 indicate that significant risk reduction for the primary endpoint (various cardiovascular outcomes) does not necessarily translate into mortality risk reduction in ESRD patients. Reasons for this discrepancy are speculative, and presumably also vary between studies. There might be a very high background morbidity in ESRD patients and a multi-faceted pathophysiology that does not allow a single medical intervention to show statistical success in mortality reduction.
It is beyond the scope of the present review to analyse in detail the pros and cons of any single study substance previously discussed. However, some comments and remarks regarding the use of some of the discussed treatments should be mentioned.
Looking at cardiovascular risk reduction in general and mortality reduction in particular, two 'beneficial' treatment strategies warrant special attention: inhibition of the renin-angiotensin system and blockade of β-receptors [48, 52] . Although these two studies are rather small and yet to be re-confirmed, we interpret the studies by Cice et al. as a clear indication to administer state-of-the-art heart failure therapy to people on dialysis with significantly reduced LVEF. Especially, the positive β-blocker data are hypothesis generating: β-blockers might be particularly capable of interacting positively with LVH, autonomic dysfunction, cardiomyopathy, arrythmias and sudden cardiac death in severe CKD. Both Cice trials reveal astonishingly low numbers-needed-to-treat. Two years of carvedilol therapy prevented 21 deaths in ∼60 patients [52] , while telmisartan was responsible for preventing 23 deaths in ∼160 patients after 3 years [48] .
Many of the above-mentioned trials calculated sample size based on the 'optimistic' assumption that their single interventional approach would reduce mortality by more than 15-20%. The 4D trial, for example, was designed to test with a power of 90%, a 27% effect size. However, in reality, at the end, 4D revealed an effect size of only 8%. If the study were powered to detect this 8% treatment effect, which may be more reasonable for a mono-intervention, the sample size would have had to be increased to over 5000 patients per arm.
What can nephrology learn from negative outcome trials?
Obviously, the ESRD patient population is a high-risk population which often presents surprisingly neutral or non-significant effects of treatment strategies in RCTs. What then are the consequences? The key message for nephrology is to keep a critical view of all apparently 'logical' treatment strategies. Therapy rationale is obviously amendable in ESRD patients when based on mere pathophysiology or just because 'they worked' in nonrenal patient populations. In consequence, some typical everyday ESRD patient care strategies are in need of a scientifically appropriate re-evaluation. Looking at everyday patient care, we postulate that testing for therapeutic combinations together with a higher number of randomized patients should be the preferred future trial target. There are many traditional and non-traditional risk factors with parallel impact on cardiovascular disease in ESRD patients. As each of them may only have a small impact on mortality, many of the RCTs in nephrology with single intervention strategies may be underpowered.
Even if there are many homologies among ESRD patients as a whole, this very particular group of patients presumably needs to be stratified using risk scores-e.g. according to concomitant left ventricular disease, the presence of cardiovascular calcifications or diabetes. It goes without further comment that a 40-year-old female with ESRD due to systemic vasculitis is much different in terms of cardiovascular risk and therapeutic risk reduction compared with a 70-year-old type 2 diabetic dialysis patient. Successful surrogate endpoint reduction should always be considered for what it is-namely soft endpoint outcome data. We do not treat biomarkers-we treat patients.
In summary, many issues in the optimized care of ESRD regarding medical improvement are unsolved. Currently, many widely applied treatment strategies for fighting cardiovascular and all-cause mortality in ESRD patients are not evidence-based. However, therapeutic neglect is not an option. To stress the positive, the absence of class A evidence provided by large RCTs allows a more personalized patient approach and avoids the mindless implementation of 'standard operating procedures' in the treatment of ESRD.
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